Blood thinning deal

29 January 2007 By Rob Cox Follow @rob1cox

Ever since the $52bn US pharmaceuticals group ousted its chief executive in September, it has been de facto on the block. Given their joint Plavix arrangement, Sanofi looks in pole position to pounce.

This content is for Subscribers only

To access full Breakingviews.com content you must be a subscriber. Please use the following link to request a trial.

Context News

Bristol Myers Squibb shares rallied more than 5% Monday after a French newspaper reported the US drug company is in talks that could lead to a takeover by France's Sanofi Aventis.

Le Lettre de l'Expansion reported the two companies have signed a preliminary merger agreement and may unveil an agreement to merge later in the year.

Bristol stock rose $1.61 to $2.82 in early trading. The companies declined to comment. Sanofi's chairman, JeanFrancois Dehecq was quoted by Bloomberg as saying I'm not ready to answer this question in a televised interview.

Email a friend

Please complete the form below.

Required fields *

Blood thinning deal

This content is for Subscribers only

Existing Users Log In

Email a friend

Please complete the form below.